Pfizer's tanezumab meets in Phase III for OA pain

Pfizer Inc. (NYSE:PFE) and partner Eli Lilly and Co. (NYSE:LLY) said tanezumab met the three co-primary endpoints compared with placebo in the Phase III A4091056 trial to treat osteoarthritis pain. Pfizer said

Read the full 325 word article

User Sign In